You are here

CometChip: Development of a high throughput DNA damage assay in hepatocytes

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2U44ES024698-04
Agency Tracking Number: U44ES024698
Amount: $2,349,785.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIEHS
Solicitation Number: ES15-016
Timeline
Solicitation Year: 2015
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-30
Award End Date (Contract End Date): 2021-06-30
Small Business Information
601 KEYSTONE PARK DR STE 100 MAILBOX B-7
Morrisville, NC 27560-0348
United States
DUNS: 130427701
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 LESLIE RECIO
 (919) 544-4589
 lrecio@ils-inc.com
Business Contact
 JULIE BISHOP
Phone: (919) 544-4589
Email: mmulleady@ils-inc.com
Research Institution
N/A
Abstract

An estimated 10,000 animals are used in toxicology safety assessments to meet all regulatory
requirements with testing spanning 5 to 10 yrs and exceeding $10 million dollars. There is a critical
need to reduce reliance on animal testing and to develop highly predictive human-based biological
models for safety assessments. Replacement of traditional animal toxicity tests for toxicology
safety assessments with alternative tests requires rigorous validations for acceptance of an
alternative method by regulatory agencies. The genetic toxicology test battery required by
regulatory agencies worldwide, directly measures DNA damage, gene mutation, chromosomal
damage in cell culture and in animals. The in vivo Comet assay in rodent liver is a component of
the required genetic toxicology test battery that detects a broad range of DNA lesions and is
considered a powerful tool to distinguish between genotoxic carcinogens and nongenotoxic
carcinogens. This regulatory assay is expensive, inefficient and can require up to 45 animals for
each test compound. We developed a medium throughput Comet assay platform (CometChip®)
using a human liver cell line HepaRG™ that maintains active, inducible spectrum of CYP450s
and Phase II enzyme cells. We have qualified this assay by testing more than 60 compounds at
Integrated Laboratory systems and MIT for use in the assessment of DNA damage and are now
able to conduct interlaboratory trials to validate this assay as a non-animal alternative to the in
vivo Comet assay. This SBIR 2B is directed at validating CometChip® technology to detect
DNA damage using metabolically competent HepaRG™ cells and hepatocytes as an in
vitro alternative to the in vivo Comet assay. This will be accomplished in four Specific Aims:
Aim 1 Conduct literature review and build database of in vivo Comet assay responses for
publication in peer-reviewed literature; Aim 2 Finalize HepaRG™ CometChip® assay specific
SOPs, quality control criteria, validation of instrumentation and GLP-compliant protocols; Specific
Aim 3 Conduct HepaRG™ CometChip® assay on 100-150 compounds per year for 3 years based
on biological activity from Tox 21; Specific Aim 4 Develop Master Validation Plan and Execute
Interlaboratory Validation; The specific purpose of this SBIR 2B application and Master Validation
Plan is to develop an in vitro alternative to the in vivo Comet assay (OECD 489) used by regulators
worldwide for the assessment of genotoxicity in liver. This SBIR 2B application is aimed validating
and translating an innovative test method developed through multiple NIH SBIR Phase II
programs as an alternative to required animals testing that will better predict how chemicals may
affect humans and the environment and reduce reliance on animals.Project Narrative
This SBIR 2B is focused on the qualification and interlaboratory validation of a novel medium
throughput genotoxicity assay in a metabolically competent human cell line HepaRG™ integrated
with a “high throughput” innovative 96 well single-cell array platforms (CometChip®) that provides
automated analysis of DNA damage. This assay referred to as the HepaRG™ CometChip®
Assay, will be aimed directly as an in vitro alternative to the in vivo Comet assay in rodent liver.
The Comet assay is part of the required genetic toxicology test battery for pharmaceuticals, is
used as a follow up for positive results from in vitro genotoxicity testing by the EU Registration,
Evaluation, Authorisation and Restriction of Chemicals (REACH) program, and uses up 40
rodents per study. HepaRG™ CometChip® Assay is being developed for use in screening of
pharmaceuticals and chemicals in safety assessment as a component of a genetic toxicology test
battery. This Phase 2B is aimed at providing the needed validations trials to meet regulatory
compliance and a submission to OECD for consideration as a Performance Based Test Guideline
reducing the need for animal testing.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government